JPWO2020020984A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020020984A5 JPWO2020020984A5 JP2021503787A JP2021503787A JPWO2020020984A5 JP WO2020020984 A5 JPWO2020020984 A5 JP WO2020020984A5 JP 2021503787 A JP2021503787 A JP 2021503787A JP 2021503787 A JP2021503787 A JP 2021503787A JP WO2020020984 A5 JPWO2020020984 A5 JP WO2020020984A5
- Authority
- JP
- Japan
- Prior art keywords
- adenosine
- strain
- lactobacillus reuteri
- production
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims 20
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims 20
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 20
- 229960005305 adenosine Drugs 0.000 claims 20
- 241000186604 Lactobacillus reuteri Species 0.000 claims 14
- 229940001882 Lactobacillus reuteri Drugs 0.000 claims 14
- 108010057533 5'-Nucleotidase Proteins 0.000 claims 9
- 102000004008 5'-Nucleotidase Human genes 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 7
- 230000001965 increased Effects 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 4
- 229950006790 Adenosine phosphate Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 210000003491 Skin Anatomy 0.000 claims 2
- 201000004384 alopecia Diseases 0.000 claims 2
- 230000003698 anagen phase Effects 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 200000000019 wound Diseases 0.000 claims 2
- 206010068168 Androgenetic alopecia Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- -1 Further Chemical compound 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 208000004113 Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000000214 Mouth Anatomy 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 230000003712 anti-aging Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 201000009608 hair disease Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (17)
該使用は、アデノシンの欠損又は減少に関連する疾患又は状態の治療又は予防のためであり、
ラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）ＤＳＭ１７９３８と比較して増加したレベルで、
５’－ヌクレオチダーゼ活性を有する、及び／又は
アデノシンを産生することができるか若しくはアデノシンの産生を誘導することができる、
上記組成物。 A composition comprising a Lactobacillus reuteri strain capable of producing or inducing the production of adenosine for use in the production of adenosine in a subject.
The use is for the treatment or prevention of diseases or conditions associated with adenosine deficiency or reduction.
At an increased level compared to Lactobacillus reuteri DSM17938,
Has 5'-nucleotidase activity and / or
Can produce or induce adenosine production,
The above composition .
５’ヌクレオチダーゼ活性において及び／又はアデノシンのレベルにおいて、ＤＳＭ１７９３８と比較して、少なくとも１．５、２、又は５倍の増加を生じさせることができる、請求項１に記載の組成物。The composition of claim 1, wherein the 5'nucleotidase activity and / or the level of adenosine can result in at least a 1.5, 2, or 5-fold increase as compared to DSM17938.
ａ）５’－ヌクレオチダーゼをコードする遺伝子の存在について乳酸菌株をスクリーニングすること、ここで該菌株がラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）である、及び／又は
ｂ）活性５’－ヌクレオチダーゼ酵素の存在について、乳酸菌株又はその上清をスクリーニングすること、ここで該菌株がラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）である、及び
ｃ）ラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）ＤＳＭ１７９３８と比較して増加したレベルで、アデノシンを産生することができるラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株を選択すること
を含み、
さらに、該方法によって選択される菌株は、対象におけるアデノシンの産生に使用するためのものである、上記方法。 A method for selecting a lactic acid strain capable of producing adenosine, wherein the strain is Lactobacillus reuteri, and the method is:
a) Screening a lactic acid strain for the presence of a gene encoding a 5'-nucleotidase, where the strain is Lactobacillus reuteri, and / or b) an active 5'-nucleotidase enzyme. Screening for the presence of a lactic acid strain or its supernatant, where the strain is Lactobacillus reuteri, and c) at an increased level compared to Lactobacillus reuteri DSM17938. , Including selecting a Lactobacillus reuteri strain capable of producing adenosine, including
Further, the strain selected by the method is for use in the production of adenosine in a subject , as described above .
（ｉ）８ユニット／Ｌを超える５’－ヌクレオチダーゼ活性を有する時、及び／又は８μｍｏｌ・Ｌ－１分－１を超えるレベルでアデノシンを産生することができる時、；並びに／或いは
（ｉｉ）ラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）ＤＳＭ１７９３８と比較して、５’ヌクレオチダーゼ活性において及び／又はアデノシンのレベルにおいて５倍までの増加を生じさせることができる時；或いは
ＤＳＭ１７９３８のレベルと比較して、５’ヌクレオチダーゼ活性において及び／又はアデノシンのレベルにおいて、少なくとも１．５、２、又は５倍の増加を生じさせることができる時、
選択される、請求項１４又は１５に記載の方法。 The strain is
(I) When having 5'-nucleotidase activity greater than 8 units / L and / or when adenosine can be produced at levels greater than 8 μmol · L -1 min -1 ; and / or
( Ii) When a 5'nucleotidase activity and / or adenosine levels can be increased up to 5-fold compared to Lactobacillus reuteri DSM17938; or
When a at least 1.5, 2, or 5-fold increase in 5'nucleotidase activity and / or adenosine levels can be produced compared to the level of DSM17938.
The method of claim 14 or 15 , which is selected.
（ｉ）アデノシンを産生することができる、又はアデノシンの産生を誘導することができる、最初のラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株と、
（ｉｉ）さらなるアデノシンの供給源、或いは該ラクトバチルス・ロイテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株によるアデノシンの産生又はアデノシンの産生の誘導を増加又は増強するための一つ以上の基質成分又は基質剤であって、該基質成分がＡＭＰ又はＡＭＰの供給源である、上記アデノシンの供給源或いは基質成分又は基質剤と
を含む、上記組み合わせ製品。 A combination product suitable for increasing adenosine production in a subject.
( I) The first Lactobacillus reuteri strain capable of producing or inducing adenosine production, and
(Ii) A further source of adenosine, or one or more substrate components or agents for increasing or enhancing the production of adenosine or the induction of adenosine production by the Lactobacillus reuteri strain. With the above-mentioned adenosine source, substrate component, or substrate agent, wherein the substrate component is AMP or a source of AMP.
Including the above combination products.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812079.0A GB201812079D0 (en) | 2018-07-24 | 2018-07-24 | Selection method |
| GB1812079.0 | 2018-07-24 | ||
| GB1905470.9 | 2019-04-17 | ||
| GBGB1905470.9A GB201905470D0 (en) | 2019-04-17 | 2019-04-17 | Selection method |
| GBGB1905591.2A GB201905591D0 (en) | 2019-04-18 | 2019-04-18 | Therapeutic method |
| GB1905591.2 | 2019-04-18 | ||
| PCT/EP2019/069987 WO2020020984A1 (en) | 2018-07-24 | 2019-07-24 | Therapeutic methods using bacterial strains which are capable of increasing adenosine levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531015A JP2021531015A (en) | 2021-11-18 |
| JPWO2020020984A5 true JPWO2020020984A5 (en) | 2022-07-05 |
Family
ID=67383783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503787A Pending JP2021531015A (en) | 2018-07-24 | 2019-07-24 | Treatment with bacterial strains that can increase adenosine levels |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230057324A1 (en) |
| EP (1) | EP3827102A1 (en) |
| JP (1) | JP2021531015A (en) |
| CN (1) | CN112739814B (en) |
| CA (1) | CA3103356A1 (en) |
| MX (1) | MX2020014222A (en) |
| WO (1) | WO2020020984A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020012770A (en) | 2018-07-24 | 2021-02-15 | Biogaia Ab | Selection and use of melatonin supporting bacteria to reduce infantile colic. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20030467A0 (en) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Procedure for treating inflammatory conditions |
| US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
| EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
| ITMI20120471A1 (en) * | 2012-03-26 | 2013-09-27 | Giovanni Mogna | COMPOSITION BASED ON BACTERIA BIFID BACTERIUM LONGUM STRIPS ABLE TO HELP THE EXTENSION OF LIFE |
| GB201206599D0 (en) * | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| EP2674162A1 (en) * | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
| PL3629026T3 (en) * | 2014-01-23 | 2021-08-02 | Biogaia Ab | Agents modulating gastrointestinal pain |
| MX2016015153A (en) * | 2014-05-20 | 2017-03-07 | Biogaia Ab | Neonatal microbiome supplementation. |
| JP6637419B2 (en) * | 2014-06-30 | 2020-01-29 | 株式会社明治 | Lactic acid bacteria inhibiting purine absorption and uses thereof |
| CA2971520C (en) * | 2014-12-23 | 2024-04-09 | Ilya Pharma Ab | Methods for wound healing |
| EP3463385A1 (en) * | 2016-05-27 | 2019-04-10 | Biogaia AB | Use of inosine for the treatment of t-reg deficiency |
| WO2017223364A1 (en) * | 2016-06-23 | 2017-12-28 | Erdman Susan E | Canine microbe preparations for increasing oxytocin |
| MX2020012770A (en) * | 2018-07-24 | 2021-02-15 | Biogaia Ab | Selection and use of melatonin supporting bacteria to reduce infantile colic. |
-
2019
- 2019-07-24 JP JP2021503787A patent/JP2021531015A/en active Pending
- 2019-07-24 MX MX2020014222A patent/MX2020014222A/en unknown
- 2019-07-24 EP EP19742228.0A patent/EP3827102A1/en active Pending
- 2019-07-24 CA CA3103356A patent/CA3103356A1/en active Pending
- 2019-07-24 WO PCT/EP2019/069987 patent/WO2020020984A1/en unknown
- 2019-07-24 CN CN201980044643.7A patent/CN112739814B/en active Active
- 2019-07-24 US US17/251,410 patent/US20230057324A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102905558A (en) | Immune imprinting nutritional composition | |
| Wilfong et al. | Zonisamide for absence seizures | |
| EP2164512A2 (en) | Methods and compositions for treating mucositis | |
| JPWO2009131208A1 (en) | Novel lactic acid bacteria having antiallergic action, antiallergic agent, food and pharmaceutical composition containing the lactic acid bacteria, and method for producing the antiallergic agent | |
| Gao et al. | Low-level vagosympathetic trunk stimulation inhibits atrial fibrillation in a rabbit model of obstructive sleep apnea | |
| KR102107443B1 (en) | Lactobacillus probiotics preparation for preventing or relieving the female menopausal symptoms | |
| JP2002526413A (en) | Reduction of oxidative stress factors | |
| JPWO2020020984A5 (en) | ||
| Crowley et al. | Microbial respiration in the Colon: using H2O2 to catch your breath | |
| Altman et al. | Effects of five hours of restraint stress on subsequent sleep in the rat | |
| US20040157813A1 (en) | Treatment of obstructive sleep apnea | |
| KR101753164B1 (en) | Production method of fermentation product for increase immunity and influeza virus cold prevention | |
| KR20110112803A (en) | Agents and treatment for snoring and respiratory effort related arousals in sleep | |
| JPWO2020020982A5 (en) | ||
| TW200836754A (en) | Prophylactic/therapeutic agent for inflammatory bowel disease | |
| Jevtic et al. | SMA-TREATMENT: EP. 281 Branaplam in type 1 spinal muscular atrophy: second and third part of a phase II study | |
| CN111011865A (en) | Health product for regulating intestines and stomach and processing method thereof | |
| KR20200039319A (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing lactobacillus animalis | |
| Pavithra et al. | Probiotics–A Miracle in Periodontal Therapy | |
| JPWO2020214083A5 (en) | ||
| CN110494146A (en) | With the method for Microrna treatment diabetic ulcer | |
| Zyuz’kov et al. | The Role of cAMP-Dependent Intracellular Signaling Pathways in the Regulation of the Functions of Neural Stem Cells and Neuroglial Cells in Amyloid-β-Induced Neurodegeneration | |
| WO2024031058A3 (en) | Compositions and methods to treat neurological diseases | |
| CN107551020B (en) | Lung moistening and cough stopping alligator oil composition | |
| RU2020138872A (en) | SELECTION AND APPLICATION OF MELATONIN PROVIDING BACTERIA FOR THE REDUCTION OF INFANT COLIC |